LLY,ENDP -

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How Analysts Rate JNJ after 1Q18 Earnings
    Market Realist11 hours ago

    How Analysts Rate JNJ after 1Q18 Earnings

    As discussed earlier, Johnson & Johnson reported a 12.6% increase in revenues to $20.0 million in 1Q18 as compared to $17.8 million in 1Q17. The increase included 8.4% growth in revenues at constant exchange rates and a 4.2% positive impact of foreign exchange.

  • Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates
    Market Realist11 hours ago

    Bristol-Myers Squibb’s 1Q18 Earnings Beat Wall Street Estimates

    Bristol-Myers Squibb (BMY) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues in 1Q18. It reported EPS of $0.94 on revenues of $5.2 billion in 1Q18 today, compared to analysts’ estimates for EPS of $0.85 on revenues of $5.2 billion.

  • $190M deal: Endo buying North Jersey specialty pharma company
    American City Business Journals12 hours ago

    $190M deal: Endo buying North Jersey specialty pharma company

    The Somerset, N.J., company that Endo is buying specializes in sterile injectable products. The deal also include a manufacturing facility in India.

  • What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?
    Market Realist12 hours ago

    What’s Johnson & Johnson’s Valuation after 1Q18 Earnings?

    As discussed earlier, Johnson & Johnson (JNJ) reported revenue growth of 12.6% in its 1Q18 revenues to $20.0 billion.

  • PR Newswire13 hours ago

    Endo to Acquire Somerset Therapeutics and Business of Affiliate Wintac Limited

    DUBLIN, April 26, 2018 /PRNewswire/ -- Endo International plc (ENDP) today announced that it has reached definitive agreements to acquire Somerset Therapeutics, LLC, a New Jersey based specialty pharmaceutical company that develops and markets sterile injectable and ophthalmic drugs for the U.S. marketplace, and the business of its India based affiliate Wintac Limited, which operates as Somerset Therapeutics' contract developer and manufacturer.  Endo is paying approximately $190 million in total for Somerset Therapeutics and Wintac's business. Together, the acquisitions will secure for Endo's Par Sterile injectable business Somerset Therapeutics' commercial and pipeline products as well as Wintac's manufacturing capabilities for those products.

  • Novo Nordisk’s Victoza Could See High Growth in 2018
    Market Realist14 hours ago

    Novo Nordisk’s Victoza Could See High Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner, which reflected a ~25% YoY (year-over-year) growth in local currency.

  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of LLY earnings conference call or presentation 24-Apr-18 1:00pm GMT

    Q1 2018 Eli Lilly and Co Earnings Call

  • Sanofi’s 1Q18: Revenue Expected to Fall
    Market Realistyesterday

    Sanofi’s 1Q18: Revenue Expected to Fall

    As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.

  • GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
    Market Realistyesterday

    GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings

    GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.

  • Novartis Launches FocalView to Modernize Clinical Trials
    Market Realistyesterday

    Novartis Launches FocalView to Modernize Clinical Trials

    Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

  • Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18
    Market Realistyesterday

    Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18

    In 1Q18, Amgen (AMGN) generated revenue of $5.6 billion, representing ~2% YoY (year-over-year) growth from its revenue of $5.5 billion in 1Q17. Quarter-over-quarter, its revenue fell ~4%. Amgen’s GAAP (generally accepted accounting principles) operating income and net income rose ~5% and ~12% YoY, respectively, to $2.7 billion and $2.3 billion from $2.6 billion and $2.1 billion.

  • How Analysts Rate Bristol-Myers Squibb in 1Q18
    Market Realistyesterday

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.

  • A Review of Novo Nordisk’s Modern Insulin
    Market Realistyesterday

    A Review of Novo Nordisk’s Modern Insulin

    Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.

  • Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
    Market Realistyesterday

    Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18

    As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.

  • Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
    Market Realistyesterday

    Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

    Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

  • Gilead Sciences has a Strong Oncology Research Program
    Market Realistyesterday

    Gilead Sciences has a Strong Oncology Research Program

    Gilead Sciences (GILD) is currently studying a combination of anti-MMP-9 (anti-matrix metalloproteinase-9) antibody andecaliximab with modified FOLFOX 6 in a Phase 3 trial as a therapy for treatment-naïve advanced gastric or GAMMA-1 (gastroesophageal junction adenocarcinoma) patients. The company also expects to conclude its Phase 2 trial comparing an andecaliximab-nivolumab combination with a nivolumab monotherapy in gastric cancer in 2018. If these trials prove successful, Gilead Sciences could emerge as major competition for other gastric cancer therapy players such as Eli Lilly (LLY) and Roche (RHHBY).

  • Why Incyte Stock Fell ~9% on April 24
    Market Realist2 days ago

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realist2 days ago

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease
    PR Newswire2 days ago

    Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease

    - Collaboration between China's National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China - The Lilly and NCCD collaboration will address ...

  • Is Eli Lilly and Company a Buy?
    Motley Fool2 days ago

    Is Eli Lilly and Company a Buy?

    Lilly's first-quarter results looked good. Is it time to buy the big pharma stock?

  • Eli Lilly Lures Bain, Advent on Animal Health Sale
    Bloomberg2 days ago

    Eli Lilly Lures Bain, Advent on Animal Health Sale

    Eli Lilly & Co. has attracted interest from private equity firms including Bain Capital and Advent International Corp. for its animal-health business, as the pharmaceutical giant considers options for ...

  • Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
    Market Realist2 days ago

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.

  • TheStreet.com2 days ago

    Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

    Stocks finished sharply lower Tuesday, as corporate earnings disappoint investors.

  • Eli Lilly Tops On Diabetes, Chemo Strength But A Key Drug Lagged
    Investor's Business Daily2 days ago

    Eli Lilly Tops On Diabetes, Chemo Strength But A Key Drug Lagged

    Eli Lilly topped the Street's first-quarter estimates Tuesday on unexpected strength from two diabetes drugs and the early impact of a chemotherapy tie with Dow Jones' component Merck.

  • Ozempic Could Be Potential Driver for Novo Nordisk in 2018
    Market Realist2 days ago

    Ozempic Could Be Potential Driver for Novo Nordisk in 2018

    In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.